The market size of US biopharmaceuticals is estimated at USD 169.45 billion in 2025 and is estimated to grow to between USD 185.21 billion in 2026 and USD 630.60 billion in 2035 and will grow by the CAGR of 14.55% between 2026 and 2035.
US Biopharmaceuticals Market Revenue and Trends
The biopharmaceutical market in the US is centered around large-molecule biologics, such as monoclonal antibodies, vaccines, cell and gene therapies, recombinant proteins, and biosimilars, to treat cancer, autoimmune, rare genetic, infectious diseases, and chronic illnesses with creative and specific mechanisms of action.
The US biopharmaceuticals market is evolving at a very high pace, owing to the rise in chronic and rare diseases, new biologic and advanced therapies being approved, more investment in the R&D pipeline, and innovations in mRNA platforms, CRISPR based editing and scalable manufacturing within the biopharma ecosystem.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the US biopharmaceuticals market?
Due to aging population, an increase in cancer and chronic diseases, and the need to provide patients with tailored and regenerative treatments, the increased demand for biopharmaceutical products has been catalyzed by the surge in oncology, autoimmune and rare disease treatments. With the further increase of healthcare spending (proportion of innovative biologics), an increasing number of patients and providers will want to target treatment options that provide better efficacy and outcomes than the conventional small-molecule drugs.
The latest technologies have brought such developments as next-generation antibody-drug conjugates, bispecific antibodies, CAR-T cell therapies, gene editing platforms, and AI-accelerated drug discovery, which make developments more accurate, less toxic, and faster to the market. Additional factors that have led to this are greater regulatory encouragement of breakthrough drugs (FDA designations), greater reimbursement and coverage of high-cost biologics, and substantial public-private funding, academic partnerships, and policy efforts that facilitate biopharma innovation.
Segment Insight
By Product Type
By products, monoclonal antibodies commanded by far the largest portion of the US biopharmaceuticals market as of 2025, with the high specificity, established efficacy, and broadening indications being the key drivers of demand, and further innovation of bispecific, multispecific, and ADCs being mentioned by large counts of clinicians and payers as better methods to enhance patient survival and quality of life.
By Distribution Channel
The hospital pharmacies and specialty pharmacies have the largest market share, and they are the main centers of both procurement, storage and dispensing of the high cost biologics as well as patient support programs, infusion services and adherence monitoring. These channels, which offer professional experience in dealing with complex cold-chain needs, reimbursement navigation, and specialized administration of injectable and infused therapies have become popular channels of distributing biopharmaceuticals.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 185.21 billion |
Projected Market Size in 2035 | USD 630.60 billion |
Market Size in 2025 | USD 169.45 billion |
CAGR Growth Rate | 14.55% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Product Type, Therapeutic Application, Drug Type, Distribution Channel and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In December 2025: Major US biopharma companies advanced multiple next-generation modalities, including expanded approvals for cell and gene therapies and increased facility expansions for manufacturing capacity to support growing clinical and commercial demand for advanced biologics.
List of the prominent players in the US Biopharmaceuticals Market:
Pfizer Inc.
Johnson & Johnson
Abbvie Inc.
Merck & Co. Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Eli Lilly and Company
Gilead Sciences Inc.
Regeneron Pharmaceuticals Inc.
Biogen Inc.
Others
The US Biopharmaceuticals Market is segmented as follows:
By Product Type
Monoclonal Antibodies
o Naked Monoclonal Antibodies
o Antibody-Drug Conjugates
o Bispecific Antibodies
Recombinant Proteins
o Recombinant Hormones
o Recombinant Growth Factors
o Recombinant Enzymes
Vaccines
o Recombinant Vaccines
o Conjugate Vaccines
o Live Attenuated Vaccines
Cell and Gene Therapies
o CAR T-Cell Therapies
o Gene Therapies
o Stem Cell Therapies
Other Products
By Therapeutic Application
Oncology
Autoimmune Disorders
Infectious Diseases
Metabolic Disorders
Cardiovascular Diseases
Neurological Disorders
Other Applications
By Drug Type
Proprietary Branded Drugs
Biosimilars
Generic Biologics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
